PL2310043T3 - Czynnik von Willebranda lub czynnik VIII i czynnik von Willebranda do leczenia koagulopatii wywołanej inhibitorami trombocytów - Google Patents

Czynnik von Willebranda lub czynnik VIII i czynnik von Willebranda do leczenia koagulopatii wywołanej inhibitorami trombocytów

Info

Publication number
PL2310043T3
PL2310043T3 PL09777111T PL09777111T PL2310043T3 PL 2310043 T3 PL2310043 T3 PL 2310043T3 PL 09777111 T PL09777111 T PL 09777111T PL 09777111 T PL09777111 T PL 09777111T PL 2310043 T3 PL2310043 T3 PL 2310043T3
Authority
PL
Poland
Prior art keywords
von willebrand
factor
willebrand factor
thrombocytes
inhibitors
Prior art date
Application number
PL09777111T
Other languages
English (en)
Other versions
PL2310043T5 (pl
Inventor
Gerhard Dickneite
Ingo Pragst
Henrique Lessa
Thorsten Haas
Stefan Zeitler
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41171229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2310043(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Publication of PL2310043T3 publication Critical patent/PL2310043T3/pl
Publication of PL2310043T5 publication Critical patent/PL2310043T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL09777111.7T 2008-07-10 2009-07-10 Czynnik viii i czynnik von willebranda do leczenia koagulopatii wywołanej inhibitorami trombocytów PL2310043T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102008032361A DE102008032361A1 (de) 2008-07-10 2008-07-10 Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie
EP09777111.7A EP2310043B2 (en) 2008-07-10 2009-07-10 Factor viii and von willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes
PCT/EP2009/005027 WO2010003687A1 (en) 2008-07-10 2009-07-10 Von willebrand factor or factor viii and von willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes

Publications (2)

Publication Number Publication Date
PL2310043T3 true PL2310043T3 (pl) 2013-02-28
PL2310043T5 PL2310043T5 (pl) 2024-02-05

Family

ID=41171229

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09777111.7T PL2310043T5 (pl) 2008-07-10 2009-07-10 Czynnik viii i czynnik von willebranda do leczenia koagulopatii wywołanej inhibitorami trombocytów

Country Status (13)

Country Link
US (2) US8603979B2 (pl)
EP (1) EP2310043B2 (pl)
JP (1) JP5653916B2 (pl)
KR (1) KR20110043654A (pl)
CN (1) CN102088999A (pl)
AU (1) AU2009268289B2 (pl)
CA (1) CA2730290C (pl)
DE (1) DE102008032361A1 (pl)
DK (1) DK2310043T4 (pl)
ES (1) ES2395855T5 (pl)
PL (1) PL2310043T5 (pl)
RU (1) RU2563236C2 (pl)
WO (1) WO2010003687A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
EP3936116A1 (en) 2007-12-28 2022-01-12 Takeda Pharmaceutical Company Limited Rrecombinant vwf containing formulations
CN102066417B (zh) * 2008-06-24 2015-11-25 奥克塔法马股份有限公司 提纯凝固因子viii的方法
DE102008032361A1 (de) * 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie
PT2349314E (pt) * 2008-10-21 2013-05-28 Baxter Int Formulações de vwf recombinante liofilizado
LT2804623T (lt) 2012-01-12 2019-12-10 Bioverativ Therapeutics Inc Chimeriniai viii faktoriaus polipeptidai ir jų panaudojimas
US20150080309A1 (en) 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
EP2662083A1 (en) 2012-05-08 2013-11-13 CSL Behring GmbH Sugar compositions for treating hemophilia a and/or von willebrand disease
CN102776260B (zh) * 2012-07-26 2015-04-29 上海泰龙生物医药科技有限公司 一种高效表达重组人凝血八因子的方法
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
CN103263663B (zh) * 2013-06-08 2016-05-04 兆科药业（合肥）有限公司 一种抗血小板溶栓素在制备治疗vwf缺陷型血管栓塞性疾病的药物中的应用
WO2014210546A1 (en) 2013-06-27 2014-12-31 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4430205A1 (de) 1994-08-26 1996-02-29 Behringwerke Ag Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung
US6518482B2 (en) 1994-09-13 2003-02-11 American National Red Cross Transgenic non-human mammals expressing human coagulation factor VIII and von Willebrand factor
DE4437544A1 (de) 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
FR2744918B1 (fr) * 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
FI974321A0 (fi) * 1997-11-25 1997-11-25 Jenny Ja Antti Wihurin Rahasto Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa
US7033994B2 (en) † 1999-12-24 2006-04-25 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Medicinal compositions for preventing and treating hemorrhagic diseases associating thrombopathy
DE102008032361A1 (de) * 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie

Also Published As

Publication number Publication date
RU2011104705A (ru) 2012-08-20
CA2730290A1 (en) 2010-01-14
RU2563236C2 (ru) 2015-09-20
US8603979B2 (en) 2013-12-10
ES2395855T3 (es) 2013-02-15
EP2310043B1 (en) 2012-09-19
ES2395855T5 (es) 2022-09-06
AU2009268289A1 (en) 2010-01-14
DK2310043T4 (da) 2022-06-20
US20110112023A1 (en) 2011-05-12
PL2310043T5 (pl) 2024-02-05
JP2011527301A (ja) 2011-10-27
AU2009268289B2 (en) 2014-11-06
US20140128325A1 (en) 2014-05-08
WO2010003687A1 (en) 2010-01-14
CA2730290C (en) 2017-02-07
DE102008032361A1 (de) 2010-01-21
EP2310043A1 (en) 2011-04-20
DK2310043T3 (da) 2013-01-07
CN102088999A (zh) 2011-06-08
JP5653916B2 (ja) 2015-01-14
EP2310043B2 (en) 2022-05-18
KR20110043654A (ko) 2011-04-27
US9095564B2 (en) 2015-08-04

Similar Documents

Publication Publication Date Title
PL2310043T3 (pl) Czynnik von Willebranda lub czynnik VIII i czynnik von Willebranda do leczenia koagulopatii wywołanej inhibitorami trombocytów
ATE550333T1 (de) 4-benzylamino-1-carboxyacyl-piperidinderivate als cetp-hemmer zur behandlung von krankheiten wie hyperlipidämie oder arteriosklerose
ATE554091T1 (de) Aminotetrahydropyrane als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes
IL209895A (en) Compounds for the prevention and / or treatment of β-amyloidoses
DE602006018936D1 (de) Flüssigkeit enthaltend trehalose zur verwendung bei der prävention von gewebeadhäsion
ATE543816T1 (de) Azacycloalkanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase
PL2078730T3 (pl) Sposób otrzymywania koncentratu czynnika von Willebranda lub kompleksu czynnik VIII/ czynnik von Willebranda oraz ich zastosowanie
DE602007010303D1 (de) Verwendung von 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen
PL2271218T3 (pl) Zastosowanie i kompozycja do leczenie otępienia
BRPI0905738A2 (pt) "conjunto de um recipiente e um fecho e fecho"
EP2349310A4 (en) POLYPEPTIDE FOR TREATING OR PREVENTING ADHESIONS
HK1164274A1 (zh) 用作線粒體通透性轉變抑制劑的丙烯酰胺衍生物
DE112007000789A5 (de) Verwendung von Bora-tetraazepentalenen
DE602006008892D1 (de) Kompaktes system zur verpackung von injizierbaren gungen
BRPI0905740A2 (pt) "fecho e recipiente"
BRPI0818204A2 (pt) fecho de recipiente
IL212544A0 (en) 7- hydroxy-benzoimidazole-4-yl-methanone derivatives and pbk inhibitors containing the same
ATE525904T1 (de) Behandlung von bananen
EP2193373A4 (en) METHODS AND KITS FOR MEASURING VON WILLEBRAND FACTOR
BRPI0822129A2 (pt) Inibidores de aldh-2c no tratamento de vício.
AT509344A5 (de) Vorrichtung zum gesteuerten auslösen von lawinen
DK2571812T3 (da) Adsorptionsmiddel indeholdende titan- og jernforbindelser
ATE516805T1 (de) Medikament zur behandlung von endometriose
DE602009000789D1 (de) Perfektionierte Vorrichtung zur Auswahl von Postartikeln
DE112010005235A5 (de) Dragiermittel zum Dragieren von Arzneimitteln und Lebensmitteln